Geron’s RYTELO faces limited revenue potential in a crowded MDS market, with predominantly 3L+ utilization and flat sequential growth. Despite a narrowed net loss, Geron remains unprofitable with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback